-
Thematic Analysis
![]()
Clinical Trials Sector Scorecard, Q2 2022 Update – Thematic Research
In Q2 2022, there was increased activity in the virtual care space. Compared to Q1 2022, Novo Nordisk initiated more trials with virtual components and posted more jobs related to virtual care. Daiichi Sankyo and Takeda are planning a study in Japan that will look at the feasibility of using a wearable device to track lifestyle habits. Sanofi announced several social initiatives, including the successful pricing of its first bond linked to improving access to essential medicine, the launch of...
-
Sector Analysis
![]()
Japan Bakery and Cereals Market Size by Categories, Distribution Channel, Market Share and Forecast, 2021-2026
The Japan bakery and cereals market size was valued at $26.4 billion in 2021. The market is expected to grow at a CAGR of more than 1% during the forecast period. The Japan bakery and cereals market research report provides insights on high growth markets to target, trends in the usage of packaging materials, types and closures category level distribution data and companies market shares.
-
Product Insights
![]()
Attention Deficit Hyperactivity Disorder (ADHD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity, and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination, and inability to sustain attention on tasks or activities. Treatment includes analeptics. The ADHD Drugs in Development market research report provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for ADHD, complete with analysis by stage of development, drug target, mechanism of...
-
Product Insights
![]()
Post-Traumatic Stress Disorder (PTSD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares, and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety, and cognitive therapy. The post-traumatic stress disorder (PTSD) drugs in development market research report provides an overview of the post-traumatic stress disorder (PTSD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for PTSD, complete with analysis...
-
Product Insights
![]()
Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases. The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia,...
-
Product Insights
![]()
Epilepsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, anxiety, loss of consciousness, and contraction or jerking of body muscles. The Epilepsy Drugs in Development market research report provides an overview of the Epilepsy pipeline landscape. The report provides comprehensive information on the...
-
Product Insights
![]()
Congestive Heart Failure (Heart Failure) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Congestive heart failure (heart failure) report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure...
-
Product Insights
![]()
Atopic Dermatitis (Atopic Eczema) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Atopic Dermatitis is an itchy inflammation of skin. Signs and symptoms of Atopic Dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender. The Atopic Dermatitis - Drugs In Development research report provides a comprehensive overview on the...
-
Product Insights
![]()
Alcohol Addiction – Global Clinical Trials Review, 2022
The alcohol addiction clinical trial report provides a comprehensive overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on number of ongoing trials).
-
Sector Analysis
![]()
Fragile X Syndrome – Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2030
The Fragile X syndrome (FXS) market size in the 2MM was valued at $21.9 million in 2020. The market is projected to grow at a CAGR of over 7% during the forecast period. Since there are currently no approved therapies available, prescribed treatments are exclusively off-label drugs that target individual symptoms of the disease. Despite behavioral and educational interventions, patients with FXS continue to present with significant impairments in their functioning throughout life. It is suggested that an FXS-specific treatment...
-
Sector Analysis
![]()
Bipolar Disorder – Global Drug Forecast and Market Analysis to 2030
GlobalData estimated that drug sales for bipolar disorder in 2020 was valued at $4.1 billion across the eight major markets (8MM) - the US, the five major European markets (5EU) (France, Germany, Italy, Spain, and the UK), Japan, and Canada. It is anticipated that the bipolar disorder market will grow at a compound annual growth rate (CAGR) of more than 1.5% during the forecast period of 2021-2030. The US market makes up the majority of total global sales, contributing to...
-
Product Insights
![]()
Autism – Global Clinical Trials Review, 2022
The autism clinical trial market research report provides an overview and top-line data relating to the clinical trials on autism. The report includes an overview of trial counts and their average enrollment in top countries conducted globally. It also includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).
-
Sector Analysis
![]()
Chronic Myeloid Leukemia (CML): Global Drug Forecast and Market Analysis to 2030
The 8MM CML market was valued at $4.25 billion in 2020, and expects sales to peak in 2023, before falling at a CAGR of more than -3% during the period 2020-2030. The market growth will be driven by the launch or expansion of four agents, an increase in prevalent cases, and increased adoption of branded second and third-generation tyrosine kinase inhibitors (TKIs). Growth will be substantially inhibited by the patent expiries of all but one of the currently marketed TKIs...
-
Product Insights
![]()
Raynauds Disease – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report provides data on the Raynaud disease clinical trial scenario. This report provides top-line data relating to the clinical trials on Raynaud Disease. The report includes an overview of trials count and their average enrollment in top countries conducted globally. The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based...
-
Product Insights
![]()
Bipolar Disorder (Manic Depression) – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report provides an overview of the bipolar disorder (manic depression) clinical trials scenario. This report provides top-line data relating to the clinical trials on bipolar disorder (manic depression). The report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for...
-
Sector Analysis
![]()
Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition
According to the Global Data’s Drugs database, it indicates that maximum of the marketed drugs is found to be small molecules, despite many of the prominent contract manufacturing organizations (CMOs) investing in advanced therapy medicinal product (ATMP) capabilities in recent years and an increasing use of biologic APIs in both the pipeline and among marketed drugs. With the increase in high potency small molecule APIs, has been driven by the rise of oncology pipeline drugs coupled with small or virtual...
-
Product Insights
![]()
Traumatic Brain Injury – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Traumatic Brain Injury - Global Clinical Trials Review, H2, 2021" provides an overview of Traumatic Brain Injury Clinical trials scenario. This report provides top line data relating to the clinical trials on Traumatic Brain Injury . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor...
-
Product Insights
![]()
Ascites – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Ascites - Global Clinical Trials Review, H2, 2021" provides an overview of Ascites Clinical trials scenario. This report provides top line data relating to the clinical trials on Ascites. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
-
Product Insights
![]()
Oligodendroglioma – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Oligodendroglioma - Global Clinical Trials Review, H2, 2021" provides an overview of Oligodendroglioma Clinical trials scenario. This report provides top line data relating to the clinical trials on Oligodendroglioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for...
-
Product Insights
![]()
Raynauds Disease – Global Clinical Trials Review, H1, 2021
GlobalData's clinical trial report, “Raynauds Disease - Global Clinical Trials Review, H1, 2021" provides an overview of Raynauds Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Raynauds Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.